Immunotherapy and chemotherapy for operable non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug called ivonescimab, given alone or with chemotherapy, before and after surgery for non-small cell lung cancer that can be removed. The goal is to see if this treatment can reduce the chance of cancer coming back and improve outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your daily activity level is good (able to do normal or light activities).
- You have non-small cell lung cancer that can be surgically removed, at stage II to IIIB.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or surgery for this lung cancer).
- You do not have certain gene changes (EGFR mutations or ALK fusion) that can affect treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
Hear when a new Perioperative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.